Rimiterol
{{Drugbox | IUPAC_name = 4-{(S)-hydroxy[(2R)-piperidin-2-yl]methyl}benzene-1,2-diol | image = Rimiterol.svg | CAS_number = 32953-89-2 | CAS_supplemental = | ATC_prefix = R03 | ATC_suffix = AC05 | ATC_supplemental = | PubChem = 36283 | DrugBank = | chemical_formula = | C=12 | H=17 | N=1 | O=3 | molecular_weight = 223.268 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }} Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Rimiterol (INN/USAN) is a third-generation β2-agonist.